Kilitch Drugs (India) Share Price

NSE
KILITCH •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or open an account for live prices.
Start SIP in Kilitch Drugs (India) Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
68.20% Gain from 52W Low
13.6
TTM PE Ratio
Above industry Median
48
Price to Book Ratio
Below industry Median
3.4
Dividend yield 1yr %
0
TTM PEG Ratio
PEG TTM is much higher than 1
6.5

Kilitch Drugs (India) Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Revenue
QuarterlyYearly
Jun 2024 - 33.4516 Cr Mar 2024 - 158.8514 Cr
Mar 2024 - 44.8188 Cr Mar 2023 - 142.517 Cr
Dec 2023 - 31.7945 Cr Mar 2022 - 117.1435 Cr
Sep 2023 - 41.2022 Cr Mar 2021 - 71.1904 Cr
Jun 2023 - 36.557 Cr Mar 2020 - 57.4455 Cr
Net Profit/Loss
QuarterlyYearly
Jun 2024 - 0.1119 Cr Mar 2024 - 13.5752 Cr
Mar 2024 - 3.6807 Cr Mar 2023 - 8.2827 Cr
Dec 2023 - 1.7416 Cr Mar 2022 - 6.2136 Cr
Sep 2023 - 5.0936 Cr Mar 2021 - 3.7666 Cr
Jun 2023 - 3.0595 Cr Mar 2020 - 0.842 Cr

Kilitch Drugs (India) Ltd shareholding Pattern

Promoter
69.2%
Public
30.8%
Promoter
69.2%
Public
30.8%
Promoter
69.2%
Public
30.8%
Promoter
69.2%
Public
30.8%
Promoter
68.2%
Public
31.8%
Promoter
68.2%
Public
31.8%

Kilitch Drugs (India) Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
14
Bearish Moving Averages
2
5Day EMA
380.90
10Day EMA
371.30
12Day EMA
368.10
20Day EMA
359.60
26Day EMA
356.20
50Day EMA
350.40
100Day EMA
348.50
200Day EMA
336.30
5Day SMA
388.80
10Day SMA
366.90
20Day SMA
351.50
30Day SMA
345.40
50Day SMA
348.60
100Day SMA
343.60
150Day SMA
355.00
200Day SMA
361.70
Delivery & Volume
Day
Combined Delivery Volume- 8695 Rs
NSE+BSE Traded Volume- 26096 Rs

Week
Combined Delivery Volume- 26616 Rs
NSE+BSE Traded Volume- 67577 Rs

Month
Combined Delivery Volume- 14456 Rs
NSE+BSE Traded Volume- 30723 Rs

Resistance & Support
380.93
Pivot
Resistance
First Resistance
386.87
Second Resistance
396.88
Third Resistance
402.82
Support
First Support
370.92
Second support
364.98
Third Support
354.97
Relative Strength Index
61.81
Money Flow Index
76.65
MACD
11.93
MACD Signal
6.45
Average True Range
17.03
Average Directional Index
25.24
Rate of Change (21)
13.22
Rate of Change (125)
7.12

Kilitch Drugs (India) Ltd Company background

Founded in: 1992
Managing director: Mukund P Mehta
Kilitch Drugs (India) Limited (KDIL) was incorporated in May, 1992 as a public limited company. The Company is a pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages. The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia. Its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms of creating safe pharmaceutical solutions.The Company went public in Feb.94 to set up a pharmaceutical formulation plant at Thane to manufacture pharmaceutical products in the form of tablets, capsules,liquid orals, ointments, creams and injectables. Even before the plant was commissioned, the company came out with a rights issue in Oct.95 to expand the injectible capacity. Commercial production at the plant at Thane commenced in 1996. The company has two divisions O T C and ethical.A Pharmaceutical formulation plant at Sanaa Republic of Yemen was set up at a cost of Rs 15 crore by entering into an agreement with AlFath Trading Corporation.It also entered into an agreement with a Miami company for the export of their medicine to West Indies, south and central America.The company entered into a contract with one of the leading company in the Republic of Yemen which it had set up at a cost of Rs 2.5cr tanning unit, which was implemented in the year 199596. The company had set up a bulk drug unit at Patalganga, Maharashtra for producing raw materials for formulations. The company exports to Sudan, Yemen, middleeast, Miami and certain south American companies. KDIL started marketing a range of injectables from the factory on ethical basis. The company also introduced a new product clueplus, BonBon Gripe Water and Kilitch Balm.The Company launched a new product BENIN in the market in 2011. During the year 201112, the Company sold its business located at Paonta Sahib, Himachal Pradesh as a going concern on a slump sale basis along with transfer of services set forth in the Business Transfer Agreement (BTA). The undertaking was sold and transferred on 28th February 2012 after getting all the necessary clearances as indicated in the BTA. It retained its Name, Trademark (Kilitch) and all other properties and assets at Mumbai. It transferred certain products by entering into a Product Transfer Agreement (PTA) with Akorn India Pvt. Ltd. (AIPL) by which the right to manufacture certain products by the Company at Mumbai were sold to AIPL.
Read More

Kilitch Drugs (India) Ltd FAQs

Kilitch Drugs (India) Ltd shares are currently priced at 376 on NSE and 370.75 on BSE as of 9/17/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Kilitch Drugs (India) Ltd [KILITCH] share was 64.19. The Kilitch Drugs (India) Ltd [KILITCH] share hit a 1-year low of Rs. 223.55 and a 1-year high of Rs. 470.

The market cap of Kilitch Drugs (India) Ltd is Rs. 606.06 Cr. as of 9/17/2024 12:00:00 AM.

The PE ratios of Kilitch Drugs (India) Ltd is 34.67 as of 9/17/2024 12:00:00 AM.

The PB ratios of Kilitch Drugs (India) Ltd is 2.71 as of 9/17/2024 12:00:00 AM

You can easily buy Kilitch Drugs (India) Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -